Aptevo Therapeutics announces at-the-market stock offering of up to $2.31 million
APVO•Aptevo Therapeutics plans to offer up to $2.31 million in common stock under its existing at-the-market agreement. Previous sales under the agreement totaled 303,157 shares and generated $11.8 million in gross proceeds.
1. Offering details
Aptevo Therapeutics plans to offer up to $2.31 million in common stock under an at-the-market offering agreement dated April 28, 2025. Roth Capital Partners is the sales agent. Previous sales under the agreement totaled 303,157 shares, generating $11.8 million in gross proceeds.
